Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 258

1.

Automated Bone Scan Index as an Imaging Biomarker to Predict Overall Survival in the Zometa European Study/SPCG11.

Reza M, Wirth M, Tammela T, Cicalese V, Veiga FG, Mulders P, Miller K, Tubaro A, Debruyne F, Patel A, Caris C, Witjes W, Thorsson O, Wollmer P, Edenbrandt L, Ohlsson M, Trägårdh E, Bjartell A.

Eur Urol Oncol. 2019 Jun 8. pii: S2588-9311(19)30069-0. doi: 10.1016/j.euo.2019.05.002. [Epub ahead of print]

PMID:
31186177
2.

Functional and Oncologic Outcomes Between Open and Robotic Radical Prostatectomy at 24-month Follow-up in the Swedish LAPPRO Trial.

Nyberg M, Hugosson J, Wiklund P, Sjoberg D, Wilderäng U, Carlsson SV, Carlsson S, Stranne J, Steineck G, Haglind E, Bjartell A; LAPPRO group.

Eur Urol Oncol. 2018 Oct;1(5):353-360. doi: 10.1016/j.euo.2018.04.012. Epub 2018 Jun 11.

3.

Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer.

Chi KN, Agarwal N, Bjartell A, Chung BH, Pereira de Santana Gomes AJ, Given R, Juárez Soto Á, Merseburger AS, Özgüroğlu M, Uemura H, Ye D, Deprince K, Naini V, Li J, Cheng S, Yu MK, Zhang K, Larsen JS, McCarthy S, Chowdhury S; TITAN Investigators.

N Engl J Med. 2019 May 31. doi: 10.1056/NEJMoa1903307. [Epub ahead of print]

PMID:
31150574
4.

Agreement between patient reported outcomes and clinical reports after radical prostatectomy - a prospective longitudinal study.

Bock D, Angenete E, Bjartell A, Hugosson J, Steineck G, Walming S, Wiklund P, Haglind E.

BMC Urol. 2019 May 8;19(1):35. doi: 10.1186/s12894-019-0467-3.

5.

Expression of tSTAT3, pSTAT3727 , and pSTAT3 705 in the epithelial cells of hormone-naïve prostate cancer.

Krzyzanowska A, Don-Doncow N, Marginean FE, Gaber A, Watson RW, Hellsten R, Bjartell A.

Prostate. 2019 May;79(7):784-797. doi: 10.1002/pros.23787. Epub 2019 Mar 24.

PMID:
30905090
6.

Associations between intraoperative factors and surgeons' self-assessed operative satisfaction.

Erestam S, Bock D, Erichsen Andersson A, Bjartell A, Carlsson S, Stinesen Kollberg K, Sjoberg D, Steineck G, Stranne J, Thorsteinsdottir T, Tyritzis S, Wallerstedt Lantz A, Wiklund P, Angenete E, Haglind E.

Surg Endosc. 2019 Mar 18. doi: 10.1007/s00464-019-06731-z. [Epub ahead of print]

PMID:
30887183
7.

New Hope in Prostate Cancer Precision Medicine? miRNA Replacement and Epigenetics.

Bjartell A.

Clin Cancer Res. 2019 May 1;25(9):2679-2681. doi: 10.1158/1078-0432.CCR-19-0061. Epub 2019 Feb 26.

PMID:
30808772
8.

Intake of individual fatty acids and risk of prostate cancer in the European prospective investigation into cancer and nutrition.

Perez-Cornago A, Huybrechts I, Appleby PN, Schmidt JA, Crowe FL, Overvad K, Tjønneland A, Kühn T, Katzke V, Trichopoulou A, Karakatsani A, Peppa E, Grioni S, Palli D, Sacerdote C, Tumino R, Bueno-de-Mesquita HB, Larrañaga N, Sánchez MJ, Quirós JR, Ardanaz E, Chirlaque MD, Agudo A, Bjartell A, Wallström P, Chajes V, Tsilidis KK, Aune D, Riboli E, Travis RC, Key TJ.

Int J Cancer. 2019 Feb 26. doi: 10.1002/ijc.32233. [Epub ahead of print]

9.

90-Day readmission after radical prostatectomy-a prospective comparison between robot-assisted and open surgery.

Wallerstedt Lantz A, Stranne J, Tyritzis SI, Bock D, Wallin D, Nilsson H, Carlsson S, Thorsteinsdottir T, Gustafsson O, Hugosson J, Bjartell A, Wiklund P, Steineck G, Haglind E.

Scand J Urol. 2019 Feb;53(1):26-33. doi: 10.1080/21681805.2018.1556729. Epub 2019 Feb 6.

PMID:
30727795
10.

Proteogenomic Characterization of Patient-Derived Xenografts Highlights the Role of REST in Neuroendocrine Differentiation of Castration-Resistant Prostate Cancer.

Flores-Morales A, Bergmann TB, Lavallee C, Batth TS, Lin D, Lerdrup M, Friis S, Bartels A, Kristensen G, Krzyzanowska A, Xue H, Fazli L, Hansen KH, Røder MA, Brasso K, Moreira JM, Bjartell A, Wang Y, Olsen JV, Collins CC, Iglesias-Gato D.

Clin Cancer Res. 2019 Jan 15;25(2):595-608. doi: 10.1158/1078-0432.CCR-18-0729. Epub 2018 Oct 1.

PMID:
30274982
11.

Medical therapy versus transurethral resection of the prostate (TURP) for the treatment of symptomatic benign prostatic enlargement (BPE): a cost minimisation analysis.

Davis NF, Jack GS, Witjes WP, Bjartell A, Caris C, Patel A, de la Taille A, Lawrentschuk N, Bolton DM, Tubaro A.

World J Urol. 2019 May;37(5):873-878. doi: 10.1007/s00345-018-2454-9. Epub 2018 Aug 25.

PMID:
30145778
12.

Health Economic Analysis of Open and Robot-assisted Laparoscopic Surgery for Prostate Cancer Within the Prospective Multicentre LAPPRO Trial.

Forsmark A, Gehrman J, Angenete E, Bjartell A, Björholt I, Carlsson S, Hugosson J, Marlow T, Stinesen-Kollberg K, Stranne J, Wallerstedt A, Wiklund P, Wilderäng U, Haglind E.

Eur Urol. 2018 Dec;74(6):816-824. doi: 10.1016/j.eururo.2018.07.038. Epub 2018 Aug 22.

13.

Phase 3 Assessment of the Automated Bone Scan Index as a Prognostic Imaging Biomarker of Overall Survival in Men With Metastatic Castration-Resistant Prostate Cancer: A Secondary Analysis of a Randomized Clinical Trial.

Armstrong AJ, Anand A, Edenbrandt L, Bondesson E, Bjartell A, Widmark A, Sternberg CN, Pili R, Tuvesson H, Nordle Ö, Carducci MA, Morris MJ.

JAMA Oncol. 2018 Jul 1;4(7):944-951. doi: 10.1001/jamaoncol.2018.1093.

14.

A prospective study to evaluate the intra-individual reproducibility of bone scans for quantitative assessment in patients with metastatic prostate cancer.

Reza M, Kaboteh R, Sadik M, Bjartell A, Wollmer P, Trägårdh E.

BMC Med Imaging. 2018 May 4;18(1):8. doi: 10.1186/s12880-018-0257-5.

15.

Role of serum response factor expression in prostate cancer biochemical recurrence.

Prencipe M, Fabre A, Murphy TB, Vargyas E, O'Neill A, Bjartell A, Tasken KA, Grytli HH, Svindland A, Berge V, Eri LM, Gallagher W, Watson RW.

Prostate. 2018 Jul;78(10):724-730. doi: 10.1002/pros.23516. Epub 2018 Apr 2.

PMID:
29608018
16.

Quality of Life After Open Radical Prostatectomy Compared with Robot-assisted Radical Prostatectomy.

Wallerstedt A, Nyberg T, Carlsson S, Thorsteinsdottir T, Stranne J, Tyritzis SI, Stinesen Kollberg K, Hugosson J, Bjartell A, Wilderäng U, Wiklund P, Steineck G, Haglind E.

Eur Urol Focus. 2018 Jan 20. pii: S2405-4569(17)30297-3. doi: 10.1016/j.euf.2017.12.010. [Epub ahead of print]

PMID:
29366855
17.

Value of Intact Prostate Specific Antigen and Human Kallikrein 2 in the 4 Kallikrein Predictive Model: An Individual Patient Data Meta-Analysis.

Vickers A, Vertosick EA, Sjoberg DD, Hamdy F, Neal D, Bjartell A, Hugosson J, Donovan JL, Villers A, Zappala S, Lilja H.

J Urol. 2018 Jun;199(6):1470-1474. doi: 10.1016/j.juro.2018.01.070. Epub 2018 Jan 31.

PMID:
29366640
18.

Cartilage oligomeric matrix protein promotes prostate cancer progression by enhancing invasion and disrupting intracellular calcium homeostasis.

Englund E, Canesin G, Papadakos KS, Vishnu N, Persson E, Reitsma B, Anand A, Jacobsson L, Helczynski L, Mulder H, Bjartell A, Blom AM.

Oncotarget. 2017 Sep 21;8(58):98298-98311. doi: 10.18632/oncotarget.21176. eCollection 2017 Nov 17.

19.

Social constraints and psychological well-being after prostate cancer: A follow-up at 12 and 24 months after surgery.

Stinesen Kollberg K, Thorsteinsdottir T, Wilderäng U, Hugosson J, Wiklund P, Bjartell A, Carlsson S, Stranne J, Haglind E, Steineck G.

Psychooncology. 2018 Feb;27(2):668-675. doi: 10.1002/pon.4561. Epub 2017 Nov 7.

PMID:
29024232
20.

Treatment with the WNT5A-mimicking peptide Foxy-5 effectively reduces the metastatic spread of WNT5A-low prostate cancer cells in an orthotopic mouse model.

Canesin G, Evans-Axelsson S, Hellsten R, Krzyzanowska A, Prasad CP, Bjartell A, Andersson T.

PLoS One. 2017 Sep 8;12(9):e0184418. doi: 10.1371/journal.pone.0184418. eCollection 2017.

21.

Plasma enterolactone and risk of prostate cancer in middle-aged Swedish men.

Wallström P, Drake I, Sonestedt E, Gullberg B, Bjartell A, Olsson H, Adlercreutz H, Tikkanen MJ, Wirfält E.

Eur J Nutr. 2018 Oct;57(7):2595-2606. doi: 10.1007/s00394-017-1530-z. Epub 2017 Sep 7.

22.

Erectile Function and Oncologic Outcomes Following Open Retropubic and Robot-assisted Radical Prostatectomy: Results from the LAParoscopic Prostatectomy Robot Open Trial.

Sooriakumaran P, Pini G, Nyberg T, Derogar M, Carlsson S, Stranne J, Bjartell A, Hugosson J, Steineck G, Wiklund PN.

Eur Urol. 2018 Apr;73(4):618-627. doi: 10.1016/j.eururo.2017.08.015. Epub 2017 Sep 4.

PMID:
28882327
23.

Bone Scan Index and Progression-free Survival Data for Progressive Metastatic Castration-resistant Prostate Cancer Patients Who Received ODM-201 in the ARADES Multicentre Study.

Reza M, Jones R, Aspegren J, Massard C, Mattila L, Mustonen M, Wollmer P, Trägårdh E, Bondesson E, Edenbrandt L, Fizazi K, Bjartell A.

Eur Urol Focus. 2016 Dec;2(5):547-552. doi: 10.1016/j.euf.2016.01.005. Epub 2016 Feb 3.

24.

Bone Scan Index as an Imaging Biomarker in Metastatic Castration-resistant Prostate Cancer: A Multicentre Study Based on Patients Treated with Abiraterone Acetate (Zytiga) in Clinical Practice.

Reza M, Ohlsson M, Kaboteh R, Anand A, Franck-Lissbrant I, Damber JE, Widmark A, Thellenberg-Karlsson C, Budäus L, Steuber T, Eichenauer T, Wollmer P, Edenbrandt L, Trägårdh E, Bjartell A.

Eur Urol Focus. 2016 Dec;2(5):540-546. doi: 10.1016/j.euf.2016.02.013. Epub 2016 Mar 9.

PMID:
28723520
25.

The Molecular Evolution of Castration-resistant Prostate Cancer.

Ceder Y, Bjartell A, Culig Z, Rubin MA, Tomlins S, Visakorpi T.

Eur Urol Focus. 2016 Dec;2(5):506-513. doi: 10.1016/j.euf.2016.11.012. Epub 2016 Dec 9. Review.

PMID:
28723516
26.

Psychological Well-being and Private and Professional Psychosocial Support After Prostate Cancer Surgery: A Follow-up at 3, 12, and 24 Months After Surgery.

Kollberg KS, Wilderäng U, Thorsteinsdottir T, Hugosson J, Wiklund P, Bjartell A, Carlsson S, Stranne J, Haglind E, Steineck G.

Eur Urol Focus. 2016 Oct;2(4):418-425. doi: 10.1016/j.euf.2015.10.005. Epub 2015 Dec 1.

PMID:
28723475
27.

Habits and self-assessed quality of life, negative intrusive thoughts and depressed mood in patients with prostate cancer: a longitudinal study.

Bock D, Angenete E, Bjartell A, Carlsson S, Steineck G, Stranne J, Thorsteinsdottir T, Wiklund P, Haglind E.

Scand J Urol. 2017 Oct;51(5):353-359. doi: 10.1080/21681805.2017.1326523. Epub 2017 Jun 16.

PMID:
28621209
28.

Type 2 diabetes, adiposity and cancer morbidity and mortality risk taking into account competing risk of noncancer deaths in a prospective cohort setting.

Drake I, Gullberg B, Sonestedt E, Stocks T, Bjartell A, Wirfält E, Wallström P, Orho-Melander M.

Int J Cancer. 2017 Sep 15;141(6):1170-1180. doi: 10.1002/ijc.30824. Epub 2017 Jun 24.

30.

Corrigendum re: "Urinary Incontinence and Erectile Dysfunction After Robotic Versus Open Radical Prostatectomy: A Prospective, Controlled, Nonrandomised Trial" [Eur Urol 2015;68:216-25].

Haglind E, Carlsson S, Stranne J, Wallerstedt A, Wilderäng U, Thorsteinsdottir T, Lagerkvist M, Damber JE, Bjartell A, Hugosson J, Wiklund P, Steineck G; LAPPRO steering committee.

Eur Urol. 2017 Sep;72(3):e81-e82. doi: 10.1016/j.eururo.2017.05.022. Epub 2017 May 25. No abstract available.

PMID:
28552613
31.

How badly did it hit? Self-assessed emotional shock upon prostate cancer diagnosis and psychological well-being: a follow-up at 3, 12, and 24 months after surgery.

Stinesen Kollberg K, Wilderäng U, Thorsteinsdottir T, Hugosson J, Wiklund P, Bjartell A, Carlsson S, Stranne J, Haglind E, Steineck G.

Acta Oncol. 2017 Jul;56(7):984-990. doi: 10.1080/0284186X.2017.1300320. Epub 2017 Mar 17.

PMID:
28303734
32.

Circulating Tumor Cells as a Marker for Progression-free Survival in Metastatic Castration-naïve Prostate Cancer.

Josefsson A, Linder A, Flondell Site D, Canesin G, Stiehm A, Anand A, Bjartell A, Damber JE, Welén K.

Prostate. 2017 Jun;77(8):849-858. doi: 10.1002/pros.23325. Epub 2017 Mar 10.

PMID:
28295408
33.

Lower prostate cancer risk in Swedish men with the androgen receptor E213 A-allele.

Bentmar Holgersson M, Ruhayel Y, Karlsson M, Giwercman A, Bjartell A, Ohlsson C, Mellström D, Ljunggren Ö, Haghsheno MA, Damber JE, Lundberg Giwercman Y.

Cancer Causes Control. 2017 Mar;28(3):227-233. doi: 10.1007/s10552-017-0859-1. Epub 2017 Feb 7.

34.

Identification of a Novel Autoimmune Peptide Epitope of Prostein in Prostate Cancer.

Pin E, Henjes F, Hong MG, Wiklund F, Magnusson P, Bjartell A, Uhlén M, Nilsson P, Schwenk JM.

J Proteome Res. 2017 Jan 6;16(1):204-216. doi: 10.1021/acs.jproteome.6b00620. Epub 2016 Oct 24.

35.

Properties of the 4-Kallikrein Panel Outside the Diagnostic Gray Zone: Meta-Analysis of Patients with Positive Digital Rectal Examination or Prostate Specific Antigen 10 ng/ml and Above.

Vickers A, Vertosick EA, Sjoberg DD, Roobol MJ, Hamdy F, Neal D, Bjartell A, Hugosson J, Donovan JL, Villers A, Zappala S, Lilja H.

J Urol. 2017 Mar;197(3 Pt 1):607-613. doi: 10.1016/j.juro.2016.09.086. Epub 2016 Sep 28.

36.

Expression of the TPα and TPβ isoforms of the thromboxane prostanoid receptor (TP) in prostate cancer: clinical significance and diagnostic potential.

Mulvaney EP, Shilling C, Eivers SB, Perry AS, Bjartell A, Kay EW, Watson RW, Kinsella BT.

Oncotarget. 2016 Nov 8;7(45):73171-73187. doi: 10.18632/oncotarget.12256.

37.

Preparedness for side effects and bother in symptomatic men after radical prostatectomy in a prospective, non-randomized trial, LAPPRO.

Derogar M, Dahlstrand H, Carlsson S, Bjartell A, Hugosson J, Axén E, Johansson E, Lagerkvist M, Nyberg T, Stranne J, Thorsteinsdottir T, Wallerstedt A, Haglind E, Wiklund P, Steineck G; LAPPRO steering committee.

Acta Oncol. 2016 Dec;55(12):1467-1476. Epub 2016 Aug 16.

PMID:
27684933
38.

Re: The Initial Detection and Partial Characterization of Circulating Tumor Cells in Neuroendocrine Prostate Cancer.

Bjartell AS.

Eur Urol. 2016 Oct;70(4):700. doi: 10.1016/j.eururo.2016.07.037. Epub 2016 Jul 29. No abstract available.

PMID:
27481179
39.

Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Extended Analysis of the Phase 3 PREVAIL Study.

Beer TM, Armstrong AJ, Rathkopf D, Loriot Y, Sternberg CN, Higano CS, Iversen P, Evans CP, Kim CS, Kimura G, Miller K, Saad F, Bjartell AS, Borre M, Mulders P, Tammela TL, Parli T, Sari S, van Os S, Theeuwes A, Tombal B.

Eur Urol. 2017 Feb;71(2):151-154. doi: 10.1016/j.eururo.2016.07.032. Epub 2016 Jul 28.

40.

A Preanalytic Validation Study of Automated Bone Scan Index: Effect on Accuracy and Reproducibility Due to the Procedural Variabilities in Bone Scan Image Acquisition.

Anand A, Morris MJ, Kaboteh R, Reza M, Trägårdh E, Matsunaga N, Edenbrandt L, Bjartell A, Larson SM, Minarik D.

J Nucl Med. 2016 Dec;57(12):1865-1871. Epub 2016 Jul 21.

41.

Expression of STAT3 in Prostate Cancer Metastases.

Don-Doncow N, Marginean F, Coleman I, Nelson PS, Ehrnström R, Krzyzanowska A, Morrissey C, Hellsten R, Bjartell A.

Eur Urol. 2017 Mar;71(3):313-316. doi: 10.1016/j.eururo.2016.06.018. Epub 2016 Jun 22.

42.

Correction: Validation of Novel Biomarkers for Prostate Cancer Progression by the Combination of Bioinformatics, Clinical and Functional Studies.

Alinezhad S, Väänänen RM, Mattsson J, Li Y, Tallgrén T, Tong Ochoa N, Bjartell A, Åkerfelt M, Taimen P, Boström PJ, Pettersson K, Nees M.

PLoS One. 2016 Jun 21;11(6):e0158255. doi: 10.1371/journal.pone.0158255. eCollection 2016.

43.

The Prognostic Impact of NK/NKT Cell Density in Periampullary Adenocarcinoma Differs by Morphological Type and Adjuvant Treatment.

Lundgren S, Warfvinge CF, Elebro J, Heby M, Nodin B, Krzyzanowska A, Bjartell A, Leandersson K, Eberhard J, Jirström K.

PLoS One. 2016 Jun 8;11(6):e0156497. doi: 10.1371/journal.pone.0156497. eCollection 2016.

44.

PBX3 is a putative biomarker of aggressive prostate cancer.

Ramberg H, Grytli HH, Nygård S, Wang W, Ögren O, Zhao S, Løvf M, Katz B, Skotheim RI, Bjartell A, Eri LM, Berge V, Svindland A, Taskén KA.

Int J Cancer. 2016 Oct 15;139(8):1810-20. doi: 10.1002/ijc.30220. Epub 2016 Jun 25.

45.

Validation of Novel Biomarkers for Prostate Cancer Progression by the Combination of Bioinformatics, Clinical and Functional Studies.

Alinezhad S, Väänänen RM, Mattsson J, Li Y, Tallgrén T, Tong Ochoa N, Bjartell A, Åkerfelt M, Taimen P, Boström PJ, Pettersson K, Nees M.

PLoS One. 2016 May 19;11(5):e0155901. doi: 10.1371/journal.pone.0155901. eCollection 2016. Erratum in: PLoS One. 2016;11(6):e0158255.

46.

Prediction of clinical progression after radical prostatectomy in a nationwide population-based cohort.

Bjartell A, Bottai M, Persson J, Bratt O, Damber JE, Stattin P, Akre O.

Scand J Urol. 2016 Aug;50(4):255-9. doi: 10.1080/21681805.2016.1183226. Epub 2016 May 18.

PMID:
27192553
47.

Making Predictive Biomarkers Readily Available.

Bjartell AS.

Eur Urol. 2016 Oct;70(4):609-610. doi: 10.1016/j.eururo.2016.05.003. Epub 2016 May 13. No abstract available.

PMID:
27184380
48.

Preclinical Characterization of 3β-(N-Acetyl l-cysteine methyl ester)-2aβ,3-dihydrogaliellalactone (GPA512), a Prodrug of a Direct STAT3 Inhibitor for the Treatment of Prostate Cancer.

Escobar Z, Bjartell A, Canesin G, Evans-Axelsson S, Sterner O, Hellsten R, Johansson MH.

J Med Chem. 2016 May 26;59(10):4551-62. doi: 10.1021/acs.jmedchem.5b01814. Epub 2016 May 3.

PMID:
27111731
49.

Quantitative Time-Resolved Fluorescence Imaging of Androgen Receptor and Prostate-Specific Antigen in Prostate Tissue Sections.

Krzyzanowska A, Lippolis G, Helczynski L, Anand A, Peltola M, Pettersson K, Lilja H, Bjartell A.

J Histochem Cytochem. 2016 May;64(5):311-22. doi: 10.1369/0022155416640466. Epub 2016 Mar 29.

50.

Accurate prediction tools in prostate cancer require consistent assessment of included variables.

Jäderling F, Nyberg T, Blomqvist L, Bjartell A, Steineck G, Carlsson S.

Scand J Urol. 2016 Aug;50(4):260-6. doi: 10.3109/21681805.2016.1145736. Epub 2016 Mar 29.

PMID:
27023103

Supplemental Content

Loading ...
Support Center